Metformin is one of the most commonly used drugs worldwide. It is currently considered first-line pharmacological agent for management of diabetes mellitus type 2. Recent studies have suggested that metformin may have further benefits, especially in the field of urologic oncology. Use of metformin has been shown to be associated with decreased incidence and improved outcomes of prostate, bladder, and kidney cancer. These studies suggest that metformin does have a future role in the prevention and management of urologic malignancies. In this review, we will discuss the latest findings in this field and its implications on the management of urologic oncology patients.
机构:
Univ Michigan, Dept Urol, Div Urol Oncol & Minimally Invas Surg, Ann Arbor, MI 48109 USAUniv Michigan, Dept Urol, Div Urol Oncol & Minimally Invas Surg, Ann Arbor, MI 48109 USA
Weizer, Alon Z.
Montgomery, Jeffrey S.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Michigan, Dept Urol, Div Urol Oncol & Minimally Invas Surg, Ann Arbor, MI 48109 USAUniv Michigan, Dept Urol, Div Urol Oncol & Minimally Invas Surg, Ann Arbor, MI 48109 USA
机构:
Tufts Univ, Dept Clin Sci, Cummings Sch Vet Med, 200 Westboro Rd, North Grafton, MA 01536 USATufts Univ, Dept Clin Sci, Cummings Sch Vet Med, 200 Westboro Rd, North Grafton, MA 01536 USA
Burgess, Kristine Elaine
DeRegis, Carol J.
论文数: 0引用数: 0
h-index: 0
机构:
Piper Mem Vet Ctr, 730 Randolph Rd, Middletown, CT 06457 USATufts Univ, Dept Clin Sci, Cummings Sch Vet Med, 200 Westboro Rd, North Grafton, MA 01536 USA